ALNYLAM PHARMACEUTICALS, INC.

Registrant on federal lobbying filings · filed 2025 to 2026

$0 Income reported

1 Clients represented

7 Filings counted

0 Former members lobbying

Income is the fees this registrant reported being paid to lobby. It also reported $2,960,000 of in-house lobbying expenses, which is what a registrant files when it lobbies for itself. Everything on this page is grouped by the registrant's LDA id (401107875), not by name.

Clients 1

ALNYLAM PHARMACEUTICALS, INC. $2,960,000 7 filings

Lobbyists named 2

CURTIS RHYNE 7 filings · through 2026 Rep. Virginia Foxx (2008-2009), House Republican Study Committee (2009-2014), Rep. Richard Hudson (2014-2017), Rep. George Holding (2017-2020)
MARGARET HERMAN 2 filings · through 2026 Legislative Aide, Senator Mark Warner (June 2017-May 2019); Legislative Assistant, Rep. Mikie Sherrill (May 2019-Jan. 2020); Senior LA, Rep. Dan Kildee (Jan. 2…

A lobbyist who previously held a covered government position must disclose it. We flag the ones whose name resolves to a member of Congress and link the ones still in our roster. The revolving door collects them across every firm.

Reported by year 2 years

2026 $1,350,000 3 filings
2025 $1,610,000 4 filings

Issues lobbied 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 7
SENATE 7

Recent filings 7 total

Q3 report

ALNYLAM PHARMACEUTICALS, INC.

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $470,000 expenses · posted Oct 20, 2026

View → Q2 report

ALNYLAM PHARMACEUTICALS, INC.

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $450,000 expenses · posted Jul 20, 2026

View → Q1 report

ALNYLAM PHARMACEUTICALS, INC.

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $430,000 expenses · posted Apr 20, 2026

View → Q4 report

ALNYLAM PHARMACEUTICALS, INC.

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $390,000 expenses · posted Jan 20, 2026

View → Q3 report

ALNYLAM PHARMACEUTICALS, INC.

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $390,000 expenses · posted Oct 20, 2025

View → Q2 report

ALNYLAM PHARMACEUTICALS, INC.

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $390,000 expenses · posted Jul 20, 2025

View → Q1 report

ALNYLAM PHARMACEUTICALS, INC.

1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $440,000 expenses · posted Apr 21, 2025

View →

Keep going

Filings through October 20, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.